News

Catch up on the most impactful headlines in ophthalmology from all of 2025 with our Year in Review.

Catch up on some of the most significant headlines in atopic dermatitis news coverage from 2025 with our Year in Review.

The FDA’s decision is based on positive results from the phase 3 THRIVE and THRIVE-2 clinical trials, which showed veligrotug’s efficacy and rapid onset of benefits.

A multi-state cross-sectional analysis linked chronic kidney disease with increased COVID-19 hospitalizations, indicating more severe disease outcomes

A review shows that real-world persistence with asthma biologics depends not only on efficacy, but also on patient perceptions and mental health.

Catch up on some of the most notable headlines in psoriasis news coverage from 2025 with our Year in Review.

Catch up on the most impactful headlines in T2D from all of 2025 with our Year in Review.

In this analysis, investigators assessed the effects of any weight-loss intervention, behavioural or pharmacological, on the severity of psoriasis as well as quality-of-life outcomes.

Study finds comparable IgE reductions with heated milk and conventional desensitization, but heated milk linked to higher anaphylaxis risk in children with cow’s milk allergy.

Discover how updated diagnostic criteria for multiple sclerosis enhance accuracy and confidence in clinical practice, utilizing advanced imaging and biomarkers.

Singhal discusses the multi-pronged impact of the Commission’s definition of obesity and how it effects clinicians, patients, and the treatment structure itself.

This study explored the potential impact of body mass index (BMI) and smoking on patients’ risk of developing hidradenitis suppurativa.

The approval is based on phase 3 SEQUOIA-HCM clinical trial. The full US Prescribing Information includes a Boxed Warning for the risk of heart failure.

A cross-sectional study compares renal transplantation with dialysis, highlighting an improved sleep quality in end-stage renal disease.

Al-Samkari discusses a potentially novel use for bevacizumab in improving outcomes for patients with lesions from non-HHT etiologies.

The decision makes nerandomilast the first and only PDE4B inhibitor with immunomodulatory and antifibrotic effects approved in this indication.

Positive topline results from the phase 2b IMPACT trial show statistically significant improvements in key noninvasive tests with pemvidutide.

Grifols’ fibrinogen concentrate is now approved for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency.

In a new post hoc analysis of 4 pivotal clinical studies in atopic dermatitis and prurigo nodularis, nemolizumab was shown to improve symptoms.

Topical steroid withdrawal remains a controversial topic in the dermatology field, given the lack of necessary data.

Cosmo Pharmaceuticals released pivotal phase 3 findings on clascoterone treatment, a potential first-in-class medication designed to target androgenetic alopecia.

In a new study, children exposed to gestational diabetes showed lower FEV1 and increased odds of current asthma at ages 8–9 years.

A cross-sectional study indicates a link between urinary levels of measured metals and metalloids and the stages of cardiovascular-kidney-metabolic syndrome.

Al-Samkari discusses the slew of HHT-related complications, their frequency, and their severity, highlighting the need for more active intervention.

Results from the ATTAIN-MAINTAIN phase 3 study have displayed orforglipron’s efficacy in maintaining weight loss without major safety concerns.

A retrospective observational cohort study identifies an association between patients undergoing peritoneal dialysis and their physical activity level.

Investigators observed rapid, sustained clinical benefits after using vixarelimab in patients living with prurigo nodularis.

Registry data show worse asthma control, more exacerbations, and higher healthcare utilization in patients with severe asthma and a comorbid sleep disorder.